Athira Pharma: Advancing Bold Therapies for Neuronal Health

July 16, 2024

Athira Pharma is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Athira’s mission is to harness the power of the neurotrophic hepatocyte growth factor (HGF) system to protect and repair neuronal networks. With a deep knowledge base, broad intellectual property, and a robust pipeline of proprietary small molecules, Athira aims to develop potentially first-in-class and next-generation therapies that offer hope to patients suffering from conditions such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS).

About Us

Why Athira?

Athira is distinguished by its unique approach to neurodegenerative disease treatment. Athira is focused on developing therapeutics that enhance the naturally occurring neurotrophic HGF system, which is critical to normal brain function and may play a key role in maintaining the health and functioning of neuronal networks. With an experienced leadership team, Athira is well-positioned to advance its groundbreaking therapies through clinical development and into the hands of patients in need.

Company Highlights:

  • Topline Clinical Data: Athira is targeting to release topline data from the late-stage clinical trial of fosgonimeton for Alzheimer’s disease by the end of September. An unblinded interim analysis recommended continuing the trial, bolstering Athira's confidence in a favorable outcome.
  • Potential of Fosgonimeton: Athira believes fosgonimeton has the potential to improve cognition and function to help improve the lives of the millions of people suffering from AD who currently have limited therapeutic options.
  • Strong Financial Position: Trading near cash, Athira has a strong balance sheet capable of supporting clinical programs through key inflection points.

Go to top